Behind the Science of Sure: Pioneering a New Era in Breast Cancer Surgery

“One of the big trends in breast cancer care is de-escalation of surgery. Can we avoid surgery altogether? Or where we need surgery, how can we make it less invasive?”

These are the questions that Chief Technology Officer Quentin Harmer, Ph.D. and the team at Endomag — now part of Hologic’s Breast & Skeletal Health Solutions division — are focused on, through the development of patient-centered innovations aimed at reducing or potentially eliminating the need for complicated breast cancer surgery.

Breast cancer has a 99% survival rate when it is caught early and has not spread outside the breast.1 And with regular screening mammograms and new technologies, cancers are being discovered sooner. 

“Many breast cancers when they are first discovered are very small, and this means that the prognosis is very good for those patients, but it also means that during surgery the cancer can be too small to see or feel,” shares Harmer.

A Magnetic Solution

To guide the surgeon, a magnetic seed — called the Magseed® marker — is placed in the tumor using imaging guidance such as ultrasound. The Magseed marker is a wire-free, magnetic seed localization method that allows surgeons to target breast tumors during breast-conserving surgery. During a procedure, the surgeon uses a magnetic probe to locate the marker, so they know which tissue to remove from the body and can spare as much healthy tissue for the patient as possible. The Magseed marker stays firmly in position until detected by the Sentimag® system for removal.2

Two men interacting with a medical device in an office setting.

With the Magseed marker technology, re-excision rates can be reduced.3 “This means that some patients may not need to have a secondary surgery,” says Emma Bickerton, Therapy Development Manager.

The Magtrace® lymphatic tracer, another technology developed by Endomag, is used during sentinel node biopsies — procedures that can help determine if breast cancer has spread to the lymph nodes. This unique tracer uses magnetic guidance to identify specific lymph nodes for removal. It eliminates the need for radioactive material,4 offering a simpler option for surgeons and patients. 

Shaping the Future of Breast Surgery 

What defines the Endomag team, now part of Hologic, is their culture of innovation. “We’re always trying to evolve — getting less invasive, working toward better outcomes for the patient,” says Tanja Odenkirk, Clinical Development Manager, who oversees real-world clinical trials for Endomag. “What also excites me is that we are looking into potentially expanding in other areas outside of breast surgery.”

Surgeon feedback is a critical part of the R&D process according to Peter Constantinou, Senior Product Development Engineer. “Our engineering approach always involves listening to our patients’ and our surgeons’ needs,” he says, pointing out one example of Endomag’s engineering approach for the new version of the Sentimag system. “With our engineering process, we developed a probe with the goal of giving surgeons as much visibility as possible.”

Quote from Quentin Harmer, Ph.D.

“Listening to surgeons is really at the heart of our design process, and that's well illustrated by the genesis of the Magseed marker. As a small startup, we already had the Magtrace lymphatic tracer for locating lymph nodes. We would be talking to surgeons at tradeshows and they would say to us, ‘Well, that's great for lymph nodes but what about something to mark the tumor as well?’ And that’s where the Magseed marker started.”
Quentin Harmer, Ph.D. Chief Technology Officer at Endomag

For hospitals, Endomag’s technologies can save time and help with capacity issues, since the magnetic marker that helps guide the surgeon can be placed in advance of a procedure. The patient doesn’t need to go to radiology or nuclear medicine on the day of surgery because they already have the marker placed, meaning that hospitals can potentially increase their capacity so more patients can be treated.

“The end products take the patient into account and everything that they're going through during their surgeries,” says Bickerton. “And I absolutely love that I get to be part of that mission. We are changing what the future of breast cancer surgery looks like.”

    1. American Cancer Society. Survival rates for breast cancer. www.cancer.org. Published March 1, 2023. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html 2. Data on file at Endomag. 0.01% migration rate in Endomag internal meta-analysis (090724) of clinical studies. Correct as of March 2025. 3. Pantiora et al (2023), Magnetic Seed vs Guidewire Breast Cancer Localization With Magnetic Lymph Node Detection: A Randomized Clinical Trial. JAMA Surg. 2024 Mar 1;159(3):239-246. doi: 10.1001/jamasurg. 4. U.S. Food & Drug Administration. FDA approves magnetic device system for guiding sentinel lymph node biopsies in certain patients with breast cancer. U.S. Food and Drug Administration. Published 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-magnetic-device-system-guiding-sentinel-lymph-node-biopsies-certain-patients-breast 
     
    The content in this piece is for informational purposes only and is not intended to be medical advice. Please contact your medical professional for specific advice regarding your health and treatment. This information is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products may be available in a particular country, please write to womenshealth@hologic.com.
    Hologic, Endomag, Magtrace, Magseed, Magseed Pro, Sentimag and associated logos are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries. Intended for medical professionals and use in the U.S. only. This is a general information tool for medical professionals and is not a complete representation of the product Instructions for Use (IFU).
    The Magtrace and Sentimag Magnetic Localization System is indicated to assist in localizing lymph nodes draining a tumor site, as part of a sentinel lymph node biopsy procedure (SLNB), in patients with breast cancer undergoing a mastectomy or lumpectomy. MagTrace is contraindicated for known hypersensitivity to iron oxide or dextran compounds, Iron overload disease, a metal implant in the axilla or in the chest, SLNB before neoadjuvant chemotherapy (NAC) where magnetic resonance imaging (MRI) will be the primary imaging used for monitoring the progress of NAC, patients identified in advance to require post-lumpectomy imaging with breast MRI. For a complete list of warnings and precautions, please see the Instructions for use for the device. 
    The Endomag Magseed® Magnetic Marker is indicated for use to radiographically mark soft tissue during a surgical procedure or for future surgical procedures. Using imaging guidance such as ultrasound or radiography or aided by non-imaging guidance (Endomag Sentimag® System) the marker is located and surgically removed with the target tissue. The Endomag Sentimag® System is the only non-imaging guidance system intended for use with the Magseed® Magnetic Marker. The EndoMag MagSeed® is not intended for use in the central nervous system, circulatory system, heart, eyes or brain. The device should not be placed in a tissue site with clinical evidence of infection. For a complete list of warnings and precautions, please see the Instructions for use for the device.